Finasteride is widely used for the treatment of benign prostatic hyperplasia (BPH). Its therapeutic ef®cacy is believed to be mediated through selective inhibition of prostatic 5a-reductase (type II). This prospective, controlled, randomized study examines various relationships between changes in tissue 5a-reductase isozyme activity, epithelial proliferative index and morphology in men with BPH treated with ®nasteride for 6 months, and correlates these with clinical response.
Introduction
Finasteride has been widely used for the treatment of symptomatic benign prostatic hyperplasia (BPH). It has been shown to reduce symptoms of bladder out¯ow obstruction and maintain improvement for at least 5 y. 1, 2 Its activity as an inhibitor of prostatic 5a-reductase has been established in vitro and this, together with recognized androgen dependence of normal and hyperplastic prostatic tissue, forms the biochemical basis for its therapeutic effects. In men with BPH, ®nasteride induces an overall signi®cant reduction in prostatic volume and modest improvement in uro¯ow within 3 months, but the therapeutic effects for the individual patient are less predictable and the factors responsible for modulating this clinical response are not well understood.
The development of BPH is dependent upon circulating androgens, synthesized mostly in the testes with less than 5% produced by the adrenal glands. Within the prostate, dihydrotestosterone (DHT) is the physiologically active androgen, having a higher af®nity for the androgen receptor than testosterone itself. DHT is produced intracellularly from testosterone by the enzymatic activity of 5a-reductase. Of the two isozymes (named types I and II), type II is predominantly responsible for DHT production within the prostate, whereas type I activity is found in other androgen sensitive tissues, including skin and liver. The therapeutic effects of ®nas-teride in BPH are believed to be mediated through selective inhibition of the type II isozyme and reduction in prostatic DHT levels. 3, 4 This prospective, controlled, randomized study was undertaken to examine cellular mechanisms in BPH tissue that may be modi®ed by 5a-reductase inhibition and in¯uence the therapeutic response to ®nasteride. It provides a quantitative assessment of morphological, biochemical changes and therapeutic effects after 6 months' treatment, including stromal and epithelial composition, selective type I and type II isozyme activity, tissue steroid receptor concentrations, epithelial proliferative activity and relates these to clinical response.
Methods
Thirty-one patients presenting with symptomatic bladder out¯ow obstruction were screened and after a 2 week run-in 30 were randomized to receive either ®nasteride or placebo (2 : 1) for 24 weeks. Three patients withdrew from the study post-randomization, two in the ®nasteride group and one in the placebo group and one died from an unrelated cause. Twenty-seven patients were evaluable, aged 55 ± 80 y (median 60 y), of whom 18 received ®nasteride and nine placebo.
Prostatic tissue was obtained by ultrasound-guided transrectal biopsies with an 18 gauge automatic biopsy needle at baseline and by transurethral resection (TURP) at the end of the trial period. In all patients, chippings studied included only those from the transition zone that had been resected from the peri-urethral prostate and immediately evacuated for¯ash freezing in liquid nitrogen at the beginning of the operation. The International Prostate Symptom Score (IPSS), uro¯ow and magnetic resonance imaging for determination of prostate volume, serum testosterone and DHT concentration were obtained at baseline and at week 24.
Total prostatic volume and transition zone volumes were calculated from sagital (S), axial (A) and coronal (C) dimensions obtained from magnetic resonance scan measurements using the formula for a prolate ellipsoid (volume 0.52 6 S 6 A 6 C). Peripheral zone volume was estimated by calculating the difference between these volumes, and the ratio of peripheral zone volume/transition zone volume (PZ/TZ) thereby determined.
Morphometric analysis of needle biopsy and TURP specimens was performed using the Zeiss AxioHOME workstation 5 using paraf®n sections stained with hematoxylin and eosin. A 500-micron grid was placed over a ®eld at 610 magni®cation. Squares were numbered sequentially and one selected from each ®eld using a random number table. Total area, glandular epithelium and gland lumen was traced in the selected grid squares and the proportion of epithelium determined by computer. Epithelium and stromal volume was estimated from a random sample of 12 ®elds and the results expressed as the stromal/epithelial ratio.
Prostatic 5a-reductase binding was analysed and V max determined for both type I and type II enzymes in BPH tissue obtained at TURP. Suf®cient tissue for the analysis was available in 20 patients, of whom 13 received ®nas-teride and seven placebo. Biochemical analysis was performed according to a method previously described. 6 Differences were analysed using the Wilcoxon rank sum test.
Epithelial proliferation fraction was evaluated immunocytochemically in paraf®n sections of the TURP specimens using the MIB-1 antibody to the nuclear antigen Ki-67. Tissue from 22 patients was evaluable, including 15 on ®nasteride and seven on placebo. The presence of in¯am-matory cell in®ltrate was noted. The percentage of positively staining cells (MIB count) was determined in three TURP chippings selected on the basis of having the most epithelium and counting cells. Usually three chippings were examined, each providing four to ®ve ®elds, giving 12 ± 15 ®elds in each patient. MIB count was also corrected for percentage glandular epithelium, calculated using a chalky point graticule array at 640 magni®cation. Student's t-test was used for statistical analysis.
Biochemical results were correlated with morphometric parameters and changes in symptom score, uroow and prostate volume.
Results

Clinical ®ndings
Improvement in uro¯ow and reduction in prostatic volume in patients treated with ®nasteride did not reach statistical signi®cance (Table 1 ). In the ®nasteride arm, there was a 16.6% reduction in prostate volume on magnetic resonance imaging. The PZ/TZ ratio changed from a median of 0.95 at baseline to 1.13 at week 24, compared to 1.42 and 1.35 respectively in the placebo group, representing a median decrease of 0.39 and 0.02 respectively.
Morphometric ®ndings
There was no statistically signi®cant difference in mean stromal/epithelial ratio at end of study between the ®nasteride group and placebo (9.50 AE 7.4 and 7.12 AE 3.55, respectively). Symptom score at end of study was positively correlated with total stromal volume at end of study (r 0.592, n 31), with worse symptoms in those men with greater stromal volume. There was a positive correlation between the total epithelial volume and the ratio of TZ/total prostate volume at week 24 (r 0.834) in the placebo group, but no such correlation among men taking ®nasteride (r 7 0.300), possibly consistent with a reduction in epithelial content in the treatment group. There was no correlation between (i) change in symptom score or change in maximum¯ow rate, and (ii) total prostatic volume, PZ/TZ ratio, total epithelial volume, total stromal volume or stromal/ epithelial ratio, either at baseline or at week 24.
5a-reductase activity
Enzymatic activity of Type I and Type II 5a-reductase isozymes was inhibited in all patients on ®nasteride ( Table 2) . Type II 5a-reductase activity was strongly inhibited in the treatment group, with over 100-fold decrease in V max . The type I isozyme was inhibited 5-fold. Thus, there was a 20/1 decrease in the ratio of mean II/I activity. Inhibition of both type I and type II isozymes was statistically signi®cant compared to placebo (P 0.005 and P 0.001 respectively). 5a-reductase activity (type I or type II) at week 24 did not correlate with change in symptom score or change in maximum¯ow rate.
No evidence was found for any correlation between 5a-reductase activity and MIB count in either the treated or the untreated group. Neither was there any correlation between (i) either 5a-reductase activity or MIB count and (ii) serum testosterone concentration or serum dihydrotestosterone concentration.
Proliferation fraction
Mean MIB counts were available in a total of 90 chippings. Among these, an in¯ammatory cell in®ltrate was present in 56 (62%). MIB count was signi®cantly greater in TURP chippings that were associated with an in¯am-matory cell in®ltrate compared with those that were not (2.02 vs 0.89, respectively; P 0.002, Student's t-test).
There was no statistically signi®cant difference in mean MIB count between patients on ®nasteride and placebo, irrespective of correction for percentage glandular epithelium (Table 3) .
In the ®nasteride group, symptom score and improvement in maximum¯ow rate was greatest in men with lowest MIB counts, and inverse correlations were observed (r 7 0.625 and r 7 0.649, respectively), whereas in the placebo group these correlations were poor (r 7 0.262 and r 7 0.317, respectively; Figures  1 and 2) . The MIB count did not correlate with change in symptom score or the ratio of TZ/total prostate volume. The same statistical relationships were observed before Figure 2 MIB count at week 24 vs total symptom score at week 24. 
Discussion
Androgens are necessary for normal development of the prostate and maintenance of its adult function. The development of BPH appears to be dependent on androgens, as it is rare in eunuchs and men with 5a-reductase de®ciency. 7 Testosterone is the major circulating androgen, mostly derived from the testes. In the prostate, it is converted to DHT by 5a-reductase. DHT interacts with the androgen receptor, initiating molecular events that ultimately mediate the androgen response. 8 Conformational changes in the androgen receptor induced by DHT enable it to bind DNA in the cell nucleus, initiating events in DNA transcription and translation within the androgen response area that results in protein synthesis. Some products have metabolic and growth regulatory functions and others are structural. BPH is associated with abnormal patterns of cellular proliferation and apoptosis, but the particular biochemical changes responsible for the abnormalities have not been characterised. A role for peptide growth factors has been postulated from the presence of these ligands and their receptors in BPH tissue, and their activity in vitro. 9 In spite of these morphological and biochemical changes, the prostate remains responsive to steroid hormones and its sensitivity to DHT in particular forms the basis for treating BPH with the 5a-reductase inhibitor, ®nasteride. Randomized clinical trials have shown that ®nasteride reduces prostatic volume by around 25% in men with symptomatic BPH thereby improving uro¯ow and symptom score. 1, 2 This bene®t has been shown to be maintained for at least ®ve years, and the progression of BPH arrested. 2, 10 Recent evidence also suggests that the need for surgery and incidence of acute urinary retention may be reduced by up to 50%. 11, 12 However, the response of individual patient may be unpredictable and improvement in symptoms score and¯ow rates may be observed in only one half of patients. 13 This study demonstrates that treatment with ®naster-ide causes a signi®cant reduction in prostatic type II 5a-reductase activity and lesser inhibition of the type I isozyme in human BPH tissue. Its selectivity for the type II isozyme is shown by the 20/1 reduction of the ratio of type II/I enzyme activity after six months of therapy. This is consistent with previous studies demonstrating time-dependent inhibition in vitro of both isozymes by ®nasteride 14 and predicting in vivo selectivity for the type II isozyme. 15 As the type II isozyme predominates in the prostate, its selective inhibition would be expected to signi®cantly reduce intracellular androgen levels, which may in turn regulate 5a-reductase expression. 16 In spite of strong inhibition of 5a-reductase activity in all treated patients, the clinical response to ®nasteride therapy varied considerably between individuals. We observed that the ratio of TZ to total prostate volume correlated with total epithelial volume in the placebo group, and that this relation was no longer observed in men treated with ®nasteride. Furthermore, total symptom score at the end of the study was greater in men with greater stromal volume. This may indicate that the improvement in symptoms seen in men treated with ®nasteride is related to reduction of epithelial volume in the hyperplastic transition zone. Unfortunately the number of subjects in this study did not provide suf®cient statistical power to establish this conclusively.
Epithelial proliferation was not signi®cantly affected by ®nasteride in this study. However, it was signi®cantly greater in association with in¯ammation. The extent and type of in¯ammation associated with increased proliferation requires further research. This study was limited by the small number of patients recruited. Also, the tissue used for analysis was taken to represent the transition zone based on prior diagnosis of BPH and site of resection, but it was not known how representative the morphological and biochemical properties measured in this tissue would be for the entire transition zone. In particular, it was unlikely to indicate the extent of in¯ammation within the entire prostate.
Several previous studies have suggested that the effects of ®nasteride occur predominantly in the prostatic epithelium, inducing atrophy and cell death, and that failure to respond may relate to stromal components. 17 ± 19 Factors that may in¯uence therapeutic ef®cacy include whole prostate volume, 20 TZ/PZ ratio 21 and the relative proportions of epithelium and stroma. 17, 19, 22 Total prostatic volume has been shown to decrease predominantly due to reduction in transition zone volume, possibly re¯ecting greater sensitivity of the inner prostate than outer prostate to the effects of ®nasteride. 17, 21, 23 However, in a more recent study examining epithelial features in men with BPH, no difference was observed between those taking ®nasteride and those receiving placebo. 24 The absence of any effect on such epithelial lesions would be consistent with the ®ndings of our study where no difference in proliferation index was observed.
This study con®rms that ®nasteride causes selective inhibition of 5a-reductase type II in human BPH tissue. However, the basis for the variability of its therapeutic activity is unclear. The greater proliferative activity in epithelium with in¯ammation and its relevance in the pathogenesis and treatment of BPH merits further investigations.
